or Try an Advanced Search...

    Technical Analysis for MNPR - Monopar Therapeutics Inc.

    Grade Last Price % Change Price Change
    D 0.60 -8.13% -0.05
    MNPR closed down 8.13 percent on Wednesday, May 15, 2024, on 61 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical MNPR trend table...
    Date Alert Name Type % Chg
    MACD Bearish Centerline Cross Bearish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    BB Squeeze + Lower Band Touch Range Contraction 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -8.13%
    MACD Bearish Signal Line Cross Bearish -8.13%
    Bollinger Band Squeeze Range Contraction -8.13%
    20 DMA Resistance Bearish -11.41%
    Older End-of-Day Signals for MNPR ...

       Recent Intraday Alerts

    Alert Time
    Lower Bollinger Band Support about 13 hours ago
    Down 5% about 14 hours ago
    Fell Below Lower Bollinger Band about 14 hours ago
    Down 10% about 14 hours ago
    Down 1 ATR about 14 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    MNPR Chart by TradingView
    Basic chart:

    Profile

    Monopar Therapeutics is a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for advanced soft tissue sarcoma; and a late-stage preclinical antibody MNPR-101.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Radiation Therapy Sarcoma Head And Neck Cancer Soft Tissue Sarcoma Mucositis Radiotherapy Oral Mucositis Otorhinolaryngology

    Is MNPR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 9 Monopar Therapeutics GAAP EPS of -$0.10
    May 9 Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
    Apr 18 Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
    Apr 16 Monopar files patent protecting its MNPR-101 radiopharma optimization findings
    Apr 16 Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
    Apr 10 Monopar initiates radiopharma phase 1 trial for its advanced cancer treatment
    Apr 10 Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
    Apr 4 Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
    Apr 3 All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
    Mar 28 Monopar Therapeutics GAAP EPS of -$0.12
    See more MNPR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.75
    52 Week Low 0.2739
    Average Volume 180,795
    200-Day Moving Average 0.56
    50-Day Moving Average 0.70
    20-Day Moving Average 0.68
    10-Day Moving Average 0.70
    Average True Range 0.08
    RSI (14) 39.76
    ADX 10.9
    +DI 20.31
    -DI 28.42
    Chandelier Exit (Long, 3 ATRs) 0.59
    Chandelier Exit (Short, 3 ATRs) 0.80
    Upper Bollinger Bands 0.77
    Lower Bollinger Band 0.58
    Percent B (%b) 0.1
    BandWidth 28.32
    MACD Line -0.01
    MACD Signal Line 0.00
    MACD Histogram -0.0069
    Fundamentals Value
    Market Cap 8.89 Million
    Num Shares 14.9 Million
    EPS -0.72
    Price-to-Earnings (P/E) Ratio -0.83
    Price-to-Sales 0.00
    Price-to-Book 0.79
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.75
    Resistance 3 (R3) 0.76 0.72 0.73
    Resistance 2 (R2) 0.72 0.68 0.71 0.72
    Resistance 1 (R1) 0.66 0.65 0.63 0.65 0.71
    Pivot Point 0.61 0.61 0.60 0.61 0.61
    Support 1 (S1) 0.55 0.57 0.53 0.55 0.49
    Support 2 (S2) 0.51 0.55 0.50 0.48
    Support 3 (S3) 0.45 0.51 0.47
    Support 4 (S4) 0.44